| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Breath of Fresh Air? Firm Type, Scale, Scope and Selection Effects in Drug Development |
0 |
0 |
0 |
0 |
0 |
1 |
5 |
223 |
| A Breath of Fresh Air? Firm types, scale, scope and selection effects in drug development |
0 |
0 |
0 |
52 |
0 |
0 |
2 |
230 |
| A powerful test of mean stationarity in dynamic models for panel data: Monte Carlo evidence |
0 |
0 |
1 |
77 |
2 |
2 |
4 |
119 |
| An LM test for the mean stationarity assumption in dynamic panel-data models |
0 |
1 |
2 |
39 |
0 |
2 |
6 |
121 |
| Autocorrelation and masked heterogeneity in panel data models estimated by maximum likelihood |
0 |
0 |
0 |
11 |
0 |
1 |
1 |
97 |
| Dinamiche di mercato e intensità della concorrenza di prezzo nel segmento dei farmaci off patent. La posizione dell'Italia nel contesto europeo |
0 |
0 |
0 |
56 |
1 |
1 |
2 |
191 |
| Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure |
0 |
0 |
1 |
150 |
0 |
1 |
3 |
514 |
| Everything You Always Wanted to Know about Inventors (But Never Asked): Evidence from the PatVal-EU Survey |
0 |
0 |
0 |
136 |
1 |
1 |
2 |
677 |
| Everything you Always Wanted to Know about Inventors (but Never Asked): Evidence from the PatVal-EU Survey |
0 |
0 |
0 |
512 |
1 |
4 |
7 |
1,659 |
| Exploiting Information from Singletons in Panel Data Analysis: A GMM Approach |
0 |
0 |
0 |
17 |
2 |
4 |
5 |
36 |
| Exploring the nexus between appropriability and productivity in highly innovative and globalised companies |
3 |
8 |
20 |
20 |
5 |
17 |
31 |
31 |
| Exploring the nexus between appropriability and productivity in highly innovative and globalized companies |
0 |
0 |
2 |
4 |
2 |
3 |
6 |
16 |
| Generici vs. Branded: confronto internazionale su prodotti off-patent rimborsati dal SSN |
0 |
0 |
0 |
16 |
1 |
2 |
2 |
100 |
| Identification of linear panel data models when instruments are not available |
0 |
0 |
0 |
60 |
0 |
0 |
0 |
153 |
| Il Decreto DL 15/04/2002, n. 63 sul Contenimento della Spesa Farmaceutica - Impatto sull'Industria e Distorsioni nel Funzionamento del Mercato |
0 |
0 |
0 |
14 |
1 |
3 |
3 |
116 |
| Il prezzo di riferimento nel quadro regolatorio del mercato farmaceutico |
0 |
0 |
0 |
23 |
1 |
3 |
4 |
145 |
| Improving GMM efficiency in dynamic models for panel data with mean stationarity |
0 |
0 |
1 |
81 |
0 |
1 |
5 |
115 |
| International Cooperation in Pharmaceutical Research |
0 |
0 |
0 |
51 |
0 |
1 |
1 |
171 |
| International Cooperation in Pharmaceutical Research |
0 |
0 |
0 |
0 |
3 |
3 |
6 |
15 |
| La spesa farmaceutica pubblica - Analisi degli ultimi anni e indicazioni per una nuova politica economica |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
74 |
| La spesa farmaceutica territoriale convenzionata: il modello FarmaRegio per l'analisi della variabilità regionale |
1 |
1 |
1 |
17 |
1 |
2 |
3 |
122 |
| Medical Devices Competitiveness and Impact on Public Health Expenditure |
0 |
1 |
3 |
192 |
0 |
6 |
23 |
793 |
| Medical Devices: Competitiveness and Impact on Public Health Expenditure |
0 |
0 |
0 |
33 |
0 |
3 |
7 |
184 |
| Moment Conditions and Neglected Endogeneity in Panel Data Models |
0 |
0 |
0 |
51 |
3 |
4 |
4 |
132 |
| Negative variance estimates in panel data models |
0 |
0 |
1 |
89 |
4 |
7 |
13 |
427 |
| Nuove politiche per l'innovazione nel settore delle scienze della vita |
0 |
0 |
0 |
7 |
1 |
2 |
4 |
101 |
| Patent Disclosure and R&D Competition in Pharmaceuticals |
0 |
0 |
0 |
110 |
2 |
3 |
5 |
199 |
| Patent Disclosure and R&D Competition in Pharmaceuticals |
0 |
0 |
0 |
117 |
1 |
4 |
7 |
326 |
| Patent Value and R&D Competition |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
106 |
| R&D and market size: who benefits from orphan drug regulation? |
0 |
0 |
0 |
76 |
2 |
3 |
6 |
200 |
| R&D, Within and Between Patent Competition in the Pharmaceutical Industry |
0 |
0 |
0 |
174 |
3 |
3 |
4 |
378 |
| Simulation-based estimation of Tobit model with random effects |
0 |
1 |
1 |
141 |
0 |
2 |
2 |
491 |
| The Identification of Time-Invariant Variables in Panel Data Model: Exploring the Role of Science in Firms’ Productivity |
0 |
0 |
3 |
26 |
5 |
6 |
13 |
48 |
| The Joint Estimate of Singleton and Longitudinal Observations: a GMM Approach for Improved Efficiency |
0 |
0 |
0 |
12 |
2 |
3 |
8 |
46 |
| The Sustainability of European Health Care Systems: Beyond Income and Ageing |
0 |
0 |
0 |
59 |
0 |
0 |
1 |
200 |
| The Sustainability of European Health Care Systems: Beyond Income and Ageing |
0 |
0 |
0 |
3 |
0 |
0 |
1 |
46 |
| The Value of Failures in Pharmaceutical R&D |
0 |
0 |
0 |
33 |
0 |
0 |
2 |
151 |
| The productivity crisis in pharmaceutical R&D |
0 |
0 |
1 |
180 |
3 |
6 |
13 |
523 |
| Total Working Papers |
4 |
12 |
37 |
2,658 |
47 |
104 |
211 |
9,276 |
LogEc is hosted by the
Örebro University School of Business.